DDInter222 DDInter1627
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Bortezomib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rufinamide
Bortezomib {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Rufinamide
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Phenytoin
Phenytoin {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Rufinamide
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Valproic acid
Valproic acid {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Rufinamide
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Phenytoin
Phenytoin {u} (Compound) binds {v} (Gene) SCN2A
SCN2A {u} (Gene) is bound by {v} (Compound) Rufinamide
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Valproic acid
Valproic acid {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rufinamide
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Valproic acid
Valproic acid {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Rufinamide
Bortezomib {u} (Compound) resembles {v} (Compound) Lacosamide
Lacosamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Rufinamide
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Primidone
Primidone {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Rufinamide
Bortezomib {u} (Compound) resembles {v} (Compound) Lacosamide
Lacosamide {u} (Compound) binds {v} (Gene) SCN10A
SCN10A {u} (Gene) is bound by {v} (Compound) Rufinamide
Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rufinamide (Compound)
Bortezomib (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Rufinamide (Compound)
Bortezomib may lead to a major life threatening interaction when taken with Phenytoin and Phenytoin (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Rufinamide (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Valproic acid and Valproic acid (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Rufinamide (Compound)
Bortezomib may lead to a major life threatening interaction when taken with Phenytoin and Phenytoin (Compound) binds SCN2A (Gene) and SCN2A (Gene) is bound by Rufinamide (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Valproic acid and Valproic acid (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rufinamide (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Valproic acid and Valproic acid (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Rufinamide (Compound)
Bortezomib (Compound) resembles Lacosamide (Compound) and Lacosamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Rufinamide (Compound)
Bortezomib may lead to a major life threatening interaction when taken with Primidone and Primidone (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Rufinamide (Compound)
Bortezomib (Compound) resembles Lacosamide (Compound) and Lacosamide (Compound) binds SCN10A (Gene) and SCN10A (Gene) is bound by Rufinamide (Compound)